What is CorDynamics?
CorDynamics operates as a premier preclinical Contract Research Organization (CRO) with a distinct focus on cardiovascular drug discovery and safety pharmacology. The company provides essential research models and sophisticated analytical techniques targeting complex pathologies, including heart failure, atrial fibrillation, and thrombosis. By delivering scientifically rigorous data, CorDynamics acts as a vital partner for global pharmaceutical and biotechnology firms, effectively streamlining the transition from early-stage research to clinical development. Their market position is defined by a commitment to high-fidelity results and a client-centric service model that addresses the unique regulatory and scientific challenges inherent in cardiovascular therapeutics.
How much funding has CorDynamics raised?
CorDynamics has raised a total of $462K across 2 funding rounds:
Debt
$150K
Debt
$312K
Debt (2020): $150K with participation from PPP
Debt (2021): $312K led by PPP
Key Investors in CorDynamics
PPP
Public-Private Partnership
What's next for CorDynamics?
With the successful acquisition of this late-stage capital, CorDynamics is well-positioned to accelerate its service innovation and infrastructure expansion. The strategic deployment of these funds will likely focus on enhancing their proprietary research models and increasing throughput for global clients navigating the rigorous demands of cardiovascular drug safety. As the firm matures, the focus will shift toward integrating advanced digital health metrics and expanding their therapeutic reach, ensuring they remain at the forefront of preclinical safety standards. This financial milestone provides the necessary runway to sustain long-term growth and maintain their competitive edge in the high-stakes CRO sector.
See full CorDynamics company page
